Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 253.58M P/E - EPS this Y 36.00% Ern Qtrly Grth -
Income -364.92M Forward P/E -0.95 EPS next Y 18.50% 50D Avg Chg -8.00%
Sales 14.58M PEG -0.04 EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 1.07 EPS next 5Y 20.30% 52W High Chg -80.00%
Recommedations 3.00 Quick Ratio 4.16 Shares Outstanding 104.36M 52W Low Chg 121.00%
Insider Own 6.27% ROA -27.91% Shares Float 73.21M Beta -
Inst Own 65.09% ROE -90.55% Shares Shorted/Prior 3.75M/2.89M Price 2.43
Gross Margin - Profit Margin - Avg. Volume 1,041,782 Target Price 2.30
Oper. Margin -1,832.33% Earnings Date May 12 Volume 2,354,470 Change 0.00%
About Zymergen Inc.

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.

ZY Chatroom

User Image yus37 Posted - 06/26/24

$ZY $AMRSQ $DNA $TWST is there any hope left for $DNA ?

User Image frontiere Posted - 6 months ago

$SLRN Accelyrin ref=$4.78 post-earnings added long in size but watching if this is indeed a bottom (will it take out the recent ATL?). 🚩with so much inst owners already, who will be the marginal new buyers to push back up? 🚩will the data be a +ve surprise? 🚩will the broad macro/mkt stand in the way or be a tailwind pre readouts? 👍 news of old CEO step down, though the new name is strange too (Mina Kim a lawyer, chief legal $ZY Zymergen - IPO $3Bn then improprieties & sold to $DNA Ginkgo for $300m). 👍 faster enrollment + nearer term catalysts in 3Q + 4Q: - Izokibep in Hidradenitis Suppurativa (HS) topline Ph3 by end of Sep - Izokibep in Uveitis (UV) topline Ph2b/3 by yearend. 👍 deeply neg EV — cash=$678.5m at 2024-03-31, burn in Qtr=$43m, 70m sh outst. 🚩Anyone bullish based on neg EV should check out $ITOS $GLPG & many smaller names below net cash & only sliding lower… Latest corp deck 16Apr: https://investors.acelyrin.com/static-files/5c90da81-2070-4a9b-893f-4f5b1d625ce8

User Image Swiss212 Posted - 04/24/24

$ZY buying Nel Asa at this price is a gift....they are building a gigafactory in US....thank me later9

User Image SorosSonosSatoshi Posted - 9 months ago

$ZY omg js that zyklon B?

User Image Nerky_Clown Posted - 1 year ago

$ORGN Chart is really shaping up here....what's the narrative? I know $ZY got bought out months back, similar business. 🤔🤔🤔🤔

User Image Stan_Vick Posted - 1 year ago

$ZY Investors ask California court to certify proposed class action against Zymergen for allegedly misleading them about flagship technology.

User Image risenhoover Posted - 03/26/23

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 03/25/23

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 03/24/23

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 03/23/23

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$ZY ZY / Zymergen Inc. Price Target Updated https://fintel.io/sfo/us/zy?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image redpanda49 Posted - 1 year ago

$DNA People act like only SPACs brought hugely overvalued companies public, yet IPOs did too. And that IPOs had a more thorough due diligence process. Take a look at $RIVN. Remember $ZY was an IPO too...

User Image BlueBioTech Posted - 1 year ago

@mbleazie @beachsidefreddy that is 100% gameplay for this year. It is Not going to be a surprise acquisition. $ZY is an example you can look into.

User Image Derpy_Derpy_Doo Posted - 1 year ago

$AMRSQ I think that the short-selling of $AMRSQ that we're seeing is being orchestrated by someone in Cathie Wood's circle. Shorting Amyris at these prices makes no sense, there's so little to gain and so much to lose. I don't know whether Cathie is the ring leader or a lieutenant, but through ARK she's been "investing in"/pumping a constellation of interrelated "synbio" companies that keep being revealed as categorical frauds ($BLI, $DNA, $TWST, $ZY). Amyris is not a fraud, and not in her portfolio, and I suspect that somewhere in the organization to which she belongs is an impetus to make Amyris and other legitimate competitors look worse than they are. Maybe this short selling is also being done with retail/sovereign (a la SoftBank) money, and maybe incineration of such funds is the objective in the long run. Consistently, nowhere in the press is a respectable short-seller saying they don't like Amyris on its merits, and so the 20% short interest is likely coming from somewhere else.

User Image samchuadX Posted - 1 year ago

lawsuit scanner for $ZY https://www.lawow.org/kunz-v-zymergen-inc-et-al-2022-09-08

User Image samchuadX Posted - 1 year ago

lawsuit scanner for $ZY https://www.lawow.org/bushansky-v-zymergen-inc-et-al-2022-09-13

User Image Liatris_spicata Posted - 2 years ago

$AMRSQ $ZY Nah, Amyris has nothing worth buying. It’s just another hair care company, albeit one that decided to flog menopause for all it’s worth. Scaling production from a couple of liters, or even a couple of hundred liters, of precision fermentation products to a couple of hundred thousand liters- anyone can do that (even though, to the best of my knowledge, nobody else has). Seriously, though, I don’t see any benefit to Gingko buying Amyris, at least at this point. I admit, I don’t fully understand Gingko’s business model, but they are so different, and right now as best I can tell, the synergies aren’t there. What Is it, over 60% of Gingko’s revenues are CoVID related? FWIW, I own both companies, although far more $AMRSQ. Distressing as it is, I may add in this downturn .

User Image justoverhere Posted - 2 years ago

@biomoon Kelly always praised $ZY tech and talent before they bought it. Has he said anything good about $AMRSQ ? I'm just wondering if Amyris has anything worth buying.

User Image redpanda49 Posted - 2 years ago

$DNA Looks like Ginkgo is taking business away from $CDXS. Might be able to buy them up for pennies like they did with $ZY, or maybe not if theres nothing to gain from it and they go bk. The same will be done with $AMRSQ with their likely squalene alternative w/ Sumitomo partnership. $DNA will be the only "gen 1" synbio company remaining

User Image jmorbit Posted - 2 years ago

$DNA holding up well...but man Cathie is in trouble..now Roku..I know a lot of longs here somehow hate amrs..but would it concern you to know she hadnt even heard of it (we asked)...she is relying on Simon and Pierce, who brought you $ZY $PACB $BLI ..will she unload this one..I doubt it..but man..not good

User Image stonktraderr Posted - 2 years ago

lawsuits scanner for $ZY https://www.lawow.org/shankar-v-zymergen-inc-et-al-2021-08-04/

User Image cctranscripts Posted - 10/31/22

Securities registration termination [Section 12(g)] https://www.conferencecalltranscripts.org/summary/?id=11445645 $ZY

User Image Quantisnow Posted - 10/31/22

$ZY đź“ś SEC Form 15-12G filed by Zymergen Inc. https://quantisnow.com/i/3604268?utm_source=stocktwits 45 seconds delayed.

Analyst Ratings
JP Morgan Neutral Jul 26, 22
Goldman Sachs Neutral Apr 13, 22
UBS Neutral Mar 24, 22
Goldman Sachs Neutral Mar 24, 22
JP Morgan Underweight Sep 27, 21
UBS Neutral Aug 31, 21
B of A Securities Underperform Aug 4, 21
Cowen & Co. Market Perform Aug 4, 21
Goldman Sachs Neutral Aug 4, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Singh Enakshi Chief Financial Offi.. Chief Financial Officer Oct 03 Sell 2.7992 3,786 10,598 462,241 10/05/22
Singh Enakshi Chief Financial Offi.. Chief Financial Officer Sep 02 Sell 2.21 3,928 8,681 466,027 09/07/22
Kim Mina Chief Legal Officer Chief Legal Officer Sep 02 Sell 2.21 3,410 7,536 298,427 09/07/22
Serber Zachariah Chief Science Office.. Chief Science Officer Sep 02 Sell 2.21 3,268 7,222 2,551,685 09/07/22
Singh Enakshi Chief Financial Offi.. Chief Financial Officer Aug 30 Sell 2.2744 15,365 34,946 469,955 09/01/22
Serber Zachariah Chief Science Office.. Chief Science Officer Aug 11 Sell 3.91 5,435 21,251 2,554,953 08/15/22
Serber Zachariah Chief Science Office.. Chief Science Officer Aug 02 Sell 2.6125 2,966 7,749 2,560,388 08/04/22
Kim Mina Chief Legal Officer Chief Legal Officer Aug 02 Sell 2.6125 3,094 8,083 301,837 08/04/22
Serber Zachariah Chief Science Office.. Chief Science Officer Jul 05 Sell 1.3223 2,797 3,698 2,563,354 07/07/22
Kim Mina Chief Legal Officer Chief Legal Officer Jul 05 Sell 1.3223 2,924 3,866 304,931 07/07/22
Kim Mina Chief Legal Officer Chief Legal Officer Jun 02 Sell 1.6776 2,939 4,930 307,855 06/06/22
Serber Zachariah Chief Science Office.. Chief Science Officer Jun 02 Sell 1.6776 2,812 4,717 2,566,151 06/06/22
Serber Zachariah Chief Science Office.. Chief Science Officer May 02 Sell 1.7903 3,082 5,518 2,568,963 05/04/22
Kim Mina Chief Legal Officer Chief Legal Officer May 02 Sell 1.7903 3,206 5,740 310,794 05/04/22
Kimball Aaron Chief Technology Off.. Chief Technology Officer Apr 01 Sell 2.89 32,639 94,327 712,644 04/05/22
Kimball Aaron Chief Technology Off.. Chief Technology Officer Mar 01 Sell 3.8138 25,000 95,345 745,283 03/03/22
Serber Zachariah Chief Science Office.. Chief Science Officer Feb 22 Sell 3.91 1,424 5,568 2,373,491 02/24/22
Serber Zachariah Chief Science Office.. Chief Science Officer Feb 14 Sell 3.9981 5,435 21,730 2,374,915 02/16/22
Serber Zachariah Chief Science Office.. Chief Science Officer Feb 07 Sell 4.3291 5,435 23,529 2,380,350 02/09/22
Kimball Aaron Chief Technology Off.. Chief Technology Officer Feb 01 Sell 5.0642 25,000 126,605 770,283 02/03/22
Serber Zachariah Chief Science Office.. Chief Science Officer Jan 31 Sell 5.0339 5,435 27,359 2,385,785 02/02/22
Serber Zachariah Chief Science Office.. Chief Science Officer Jan 24 Sell 4.7605 21,730 103,446 2,391,220 01/26/22
Kimball Aaron Chief Technology Off.. Chief Technology Officer Jan 18 Sell 5.1816 50,000 259,080 795,283 01/20/22